These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 26729008)

  • 21. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
    Régnier SA
    Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Antidepressants in Combination with Psychotherapy.
    Alemi F; Soylu TG; Cannon M; McCandless C
    J Ment Health Policy Econ; 2024 Mar; 27(1):3-12. PubMed ID: 38634393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited options to manage specialty drug spending.
    Tu HT; Samuel DR
    Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health Plans' Early Response to Federal Parity Legislation for Mental Health and Addiction Services.
    Horgan CM; Hodgkin D; Stewart MT; Quinn A; Merrick EL; Reif S; Garnick DW; Creedon TB
    Psychiatr Serv; 2016 Feb; 67(2):162-8. PubMed ID: 26369886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.
    Margolis JM; Cao Z; Onukwugha E; Sanchez RJ; Alvir J; Joshi AV; Mullins CD
    Am J Manag Care; 2010 Jun; 16(6):447-56. PubMed ID: 20560688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to Addiction Pharmacotherapy in Private Health Plans.
    Reif S; Horgan CM; Hodgkin D; Matteucci AM; Creedon TB; Stewart MT
    J Subst Abuse Treat; 2016 Jul; 66():23-9. PubMed ID: 27211993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost sharing and branded antidepressant initiation among patients treated with generics.
    Buxbaum JD; Chernew ME; Bonafede M; Vlahiotis A; Walter D; Mucha L; Fendrick AM
    Am J Manag Care; 2018 Apr; 24(4):180-186. PubMed ID: 29668208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
    Mullins CD; Palumbo FB; Saba M
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.
    Wang PS; Patrick AR; Dormuth C; Maclure M; Avorn J; Canning CF; Schneeweiss S
    J Ment Health Policy Econ; 2010 Mar; 13(1):37-44. PubMed ID: 20571181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescription drugs: elderly enrollee reports of financial access, receipt of free samples, and discussion of generic equivalents related to type of coverage.
    Taira DA; Iwane KA; Chung RS
    Am J Manag Care; 2003 Apr; 9(4):305-12. PubMed ID: 12703674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
    Fairman KA; Motheral BR; Henderson RR
    Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures.
    Mark TL; Gibson TM; McGuigan K; Chu BC
    Am J Psychiatry; 2010 Oct; 167(10):1202-9. PubMed ID: 20713497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.
    Motheral B; Fairman KA
    Med Care; 2001 Dec; 39(12):1293-304. PubMed ID: 11717571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using time-series intervention analysis to understand U.S. Medicaid expenditures on antidepressant agents.
    Ferrand Y; Kelton CM; Guo JJ; Levy MS; Yu Y
    Res Social Adm Pharm; 2011 Mar; 7(1):64-80. PubMed ID: 21397882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A waste of time.
    Van Loon J
    Minn Med; 2011 Oct; 94(10):72. PubMed ID: 23256290
    [No Abstract]   [Full Text] [Related]  

  • 40. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system.
    Dunn JD; Cannon E; Mitchell MP; Curtiss FR
    J Manag Care Pharm; 2006 May; 12(4):294-302. PubMed ID: 16792435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.